Yayın:
Pharmacokinetics, bioavailability and plasma protein binding of tolfenamic acid in rainbow trout (Oncorhynchus mykiss)

dc.contributor.authorCorum, Orhan
dc.contributor.authorDurna Corum, Duygu
dc.contributor.authorMarin, Pedro
dc.contributor.authorAcar, Omer Faruk
dc.contributor.authorAksoy, Mert
dc.contributor.authorUney, Kamil
dc.date.accessioned2026-01-04T20:37:44Z
dc.date.issued2024-07-01
dc.description.abstractAbstractBackgroundAlthough research on the mechanism and control of pain and inflammation in fish has increased in recent years, the use of analgesic drugs is limited due to the lack of pharmacological information about analgesic drugs. Tolfenamic acid is a non‐steroidal anti‐inflammatory drug and can be used in fish due to its low side effect profile and superior pharmacokinetic properties.ObjectivesThe pharmacokinetics, bioavailability and plasma protein binding of tolfenamic acid were investigated following single intravascular (IV), intramuscular (IM) and oral administration of 2 mg/kg in rainbow trout at 13 ± 0.5°C.MethodsThe experiment was carried out on a total of 234 rainbow trout (Oncorhynchus mykiss). Tolfenamic acid was administered to fish via IV, IM and oral route at a dose of 2 mg/kg. Blood samples were taken at 13 different sampling times until the 72 h after drug administration. The plasma concentrations of tolfenamic acid were quantified using high pressure liquid chromatography–ultraviolet (UV) and pharmacokinetic parameters were assessed using non‐compartmental analysis.ResultsThe elimination half‐life (t1/2ʎz) of tolfenamic acid for IV, IM and oral routes was 3.47, 6.75 and 9.19 h, respectively. For the IV route, the volume of distribution at a steady state and total body clearance of tolfenamic acid were 0.09 L/kg and 0.03 L/h/kg, respectively. The peak plasma concentration and bioavailability for IM and oral administration were 8.82 and 1.24 µg/mL, and 78.45% and 21.48%, respectively. The mean plasma protein binding ratio of tolfenamic acid in rainbow trout was 99.48% and was not concentration dependent.ConclusionsWhile IM route, which exhibits both the high plasma concentration and bioavailability, can be used in rainbow trout, oral route is not recommended due to low plasma concentration and bioavailability. However, there is a need to demonstrate the pharmacodynamic activity of tolfenamic acid in rainbow trout.
dc.description.urihttps://doi.org/10.1002/vms3.1533
dc.description.urihttps://pubmed.ncbi.nlm.nih.gov/38952278
dc.description.urihttp://dx.doi.org/10.1002/vms3.1533
dc.description.urihttps://doaj.org/article/f1c4f21fb9ff4cfbb772129915126d81
dc.description.urihttps://hdl.handle.net/20.500.12483/8166
dc.identifier.doi10.1002/vms3.1533
dc.identifier.eissn2053-1095
dc.identifier.issn2053-1095
dc.identifier.openairedoi_dedup___::c4cb83cbeb2bc201f76d1a4f2650fa09
dc.identifier.orcid0000-0003-3168-2510
dc.identifier.orcid0000-0003-1567-991x
dc.identifier.orcid0000-0003-4849-4452
dc.identifier.orcid0000-0002-8674-4873
dc.identifier.pubmed38952278
dc.identifier.scopus2-s2.0-85197292876
dc.identifier.urihttps://hdl.handle.net/20.500.12597/41930
dc.identifier.volume10
dc.identifier.wos001260319600001
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofVeterinary Medicine and Science
dc.rightsOPEN
dc.subjectplasma protein binding
dc.subjectVeterinary medicine
dc.subjectAnti-Inflammatory Agents, Non-Steroidal
dc.subjectBiological Availability
dc.subjectAdministration, Oral
dc.subjectOTHER
dc.subjectBlood Proteins
dc.subjecttolfenamic acid
dc.subjectrainbow trout
dc.subjectInjections, Intramuscular
dc.subjectOncorhynchus mykiss
dc.subjectSF600-1100
dc.subjectInjections, Intravenous
dc.subjectAnimals
dc.subjectortho-Aminobenzoates
dc.subjectbioavailability
dc.subjectpharmacokinetics
dc.subjectProtein Binding
dc.subjectHalf-Life
dc.subject.sdg14. Life underwater
dc.titlePharmacokinetics, bioavailability and plasma protein binding of tolfenamic acid in rainbow trout (Oncorhynchus mykiss)
dc.typeArticle
dspace.entity.typePublication
local.api.response{"authors":[{"fullName":"Orhan Corum","name":"Orhan","surname":"Corum","rank":1,"pid":{"id":{"scheme":"orcid","value":"0000-0003-3168-2510"},"provenance":null}},{"fullName":"Duygu Durna Corum","name":"Duygu","surname":"Durna Corum","rank":2,"pid":{"id":{"scheme":"orcid_pending","value":"0000-0003-1567-991x"},"provenance":null}},{"fullName":"Pedro Marin","name":"Pedro","surname":"Marin","rank":3,"pid":{"id":{"scheme":"orcid_pending","value":"0000-0003-4849-4452"},"provenance":null}},{"fullName":"Omer Faruk Acar","name":"Omer Faruk","surname":"Acar","rank":4,"pid":null},{"fullName":"Mert Aksoy","name":"Mert","surname":"Aksoy","rank":5,"pid":null},{"fullName":"Kamil Uney","name":"Kamil","surname":"Uney","rank":6,"pid":{"id":{"scheme":"orcid","value":"0000-0002-8674-4873"},"provenance":null}}],"openAccessColor":"gold","publiclyFunded":false,"type":"publication","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"keyword","value":"plasma protein binding"},"provenance":null},{"subject":{"scheme":"keyword","value":"Veterinary medicine"},"provenance":null},{"subject":{"scheme":"keyword","value":"Anti-Inflammatory Agents, Non-Steroidal"},"provenance":null},{"subject":{"scheme":"keyword","value":"Biological Availability"},"provenance":null},{"subject":{"scheme":"keyword","value":"Administration, Oral"},"provenance":null},{"subject":{"scheme":"keyword","value":"OTHER"},"provenance":null},{"subject":{"scheme":"keyword","value":"Blood Proteins"},"provenance":null},{"subject":{"scheme":"keyword","value":"tolfenamic acid"},"provenance":null},{"subject":{"scheme":"keyword","value":"rainbow trout"},"provenance":null},{"subject":{"scheme":"keyword","value":"Injections, Intramuscular"},"provenance":null},{"subject":{"scheme":"keyword","value":"Oncorhynchus mykiss"},"provenance":null},{"subject":{"scheme":"keyword","value":"SF600-1100"},"provenance":null},{"subject":{"scheme":"keyword","value":"Injections, Intravenous"},"provenance":null},{"subject":{"scheme":"keyword","value":"Animals"},"provenance":null},{"subject":{"scheme":"keyword","value":"ortho-Aminobenzoates"},"provenance":null},{"subject":{"scheme":"SDG","value":"14. Life underwater"},"provenance":null},{"subject":{"scheme":"keyword","value":"bioavailability"},"provenance":null},{"subject":{"scheme":"keyword","value":"pharmacokinetics"},"provenance":null},{"subject":{"scheme":"keyword","value":"Protein Binding"},"provenance":null},{"subject":{"scheme":"keyword","value":"Half-Life"},"provenance":null}],"mainTitle":"Pharmacokinetics, bioavailability and plasma protein binding of tolfenamic acid in rainbow trout (<i>Oncorhynchus mykiss</i>)","subTitle":null,"descriptions":["<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Although research on the mechanism and control of pain and inflammation in fish has increased in recent years, the use of analgesic drugs is limited due to the lack of pharmacological information about analgesic drugs. Tolfenamic acid is a non‐steroidal anti‐inflammatory drug and can be used in fish due to its low side effect profile and superior pharmacokinetic properties.</jats:p></jats:sec><jats:sec><jats:title>Objectives</jats:title><jats:p>The pharmacokinetics, bioavailability and plasma protein binding of tolfenamic acid were investigated following single intravascular (IV), intramuscular (IM) and oral administration of 2 mg/kg in rainbow trout at 13 ± 0.5°C.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>The experiment was carried out on a total of 234 rainbow trout (<jats:italic>Oncorhynchus mykiss</jats:italic>). Tolfenamic acid was administered to fish via IV, IM and oral route at a dose of 2 mg/kg. Blood samples were taken at 13 different sampling times until the 72 h after drug administration. The plasma concentrations of tolfenamic acid were quantified using high pressure liquid chromatography–ultraviolet (UV) and pharmacokinetic parameters were assessed using non‐compartmental analysis.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The elimination half‐life (<jats:italic>t</jats:italic><jats:sub>1/2ʎz</jats:sub>) of tolfenamic acid for IV, IM and oral routes was 3.47, 6.75 and 9.19 h, respectively. For the IV route, the volume of distribution at a steady state and total body clearance of tolfenamic acid were 0.09 L/kg and 0.03 L/h/kg, respectively. The peak plasma concentration and bioavailability for IM and oral administration were 8.82 and 1.24 µg/mL, and 78.45% and 21.48%, respectively. The mean plasma protein binding ratio of tolfenamic acid in rainbow trout was 99.48% and was not concentration dependent.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>While IM route, which exhibits both the high plasma concentration and bioavailability, can be used in rainbow trout, oral route is not recommended due to low plasma concentration and bioavailability. However, there is a need to demonstrate the pharmacodynamic activity of tolfenamic acid in rainbow trout.</jats:p></jats:sec>"],"publicationDate":"2024-07-01","publisher":"Wiley","embargoEndDate":null,"sources":["Crossref","Vet Med Sci","Veterinary Medicine and Science, Vol 10, Iss 4, Pp n/a-n/a (2024)"],"formats":["application/pdf"],"contributors":null,"coverages":null,"bestAccessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":{"name":"Veterinary Medicine and Science","issnPrinted":"2053-1095","issnOnline":"2053-1095","issnLinking":null,"ep":null,"iss":null,"sp":null,"vol":"10","edition":null,"conferencePlace":null,"conferenceDate":null},"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"doi_dedup___::c4cb83cbeb2bc201f76d1a4f2650fa09","originalIds":["10.1002/vms3.1533","50|doiboost____|c4cb83cbeb2bc201f76d1a4f2650fa09","od_______267::bfa31e76424c599084bc932ec69719ca","38952278","PMC11217592","oai:pubmedcentral.nih.gov:11217592","50|od_______267::bfa31e76424c599084bc932ec69719ca","oai:doaj.org/article:f1c4f21fb9ff4cfbb772129915126d81","50|doajarticles::ed1d6d65b17ffb4e63dffbde628bcb4c","oai:openaccess.mku.edu.tr:20.500.12483/8166","50|od______4778::e307cf53e076d66da4f460f8cbbad99c"],"pids":[{"scheme":"doi","value":"10.1002/vms3.1533"},{"scheme":"pmid","value":"38952278"},{"scheme":"pmc","value":"PMC11217592"},{"scheme":"handle","value":"20.500.12483/8166"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":3,"influence":2.682716e-9,"popularity":4.824747e-9,"impulse":3,"citationClass":"C5","influenceClass":"C5","impulseClass":"C5","popularityClass":"C4"}},"instances":[{"pids":[{"scheme":"doi","value":"10.1002/vms3.1533"}],"license":"CC BY","type":"Article","urls":["https://doi.org/10.1002/vms3.1533"],"publicationDate":"2024-07-01","refereed":"peerReviewed"},{"pids":[{"scheme":"pmid","value":"38952278"},{"scheme":"pmc","value":"PMC11217592"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1002/vms3.1533"}],"type":"Article","urls":["https://pubmed.ncbi.nlm.nih.gov/38952278"],"publicationDate":"2024-07-02","refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.1002/vms3.1533"}],"license":"CC BY","type":"Other literature type","urls":["http://dx.doi.org/10.1002/vms3.1533"],"publicationDate":"2024-07-02","refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.1002/vms3.1533"}],"type":"Article","urls":["https://doaj.org/article/f1c4f21fb9ff4cfbb772129915126d81"],"publicationDate":"2024-07-01","refereed":"nonPeerReviewed"},{"pids":[{"scheme":"handle","value":"20.500.12483/8166"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1002/vms3.1533"}],"type":"Article","urls":["https://hdl.handle.net/20.500.12483/8166","https://doi.org/10.1002/vms3.1533"],"publicationDate":"2024-09-18","refereed":"nonPeerReviewed"}],"isGreen":true,"isInDiamondJournal":false}
local.import.sourceOpenAire
local.indexed.atWOS
local.indexed.atScopus
local.indexed.atPubMed

Dosyalar

Koleksiyonlar